文献速递帕金森病与运动障碍

灵活剂量tavapadon治疗早期帕金森病的3期随机对照试验

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.
PubMed 文献 · Lancet Neurol · 2026-01-01

TEMPO-2是一项3期随机双盲安慰剂对照试验,纳入304例早期帕金森病患者,评估灵活剂量tavapadon(5-15 mg/日)的疗效与安全性。不良事件以轻中度为主,恶心、头痛、头晕较安慰剂更常见。

要点

  • tavapadon显著改善早期帕金森病运动症状和日常生活能力。
  • 常见不良事件为恶心、头痛、头晕,多为轻中度。
  • 嗜睡和冲动控制障碍发生率低,但观察期短。

核心结论

  • 灵活剂量tavapadon(5-15 mg)每日一次可显著改善早期帕金森病患者的MDS-UPDRS II+III评分,且嗜睡和冲动控制障碍发生率低。

研究设计与样本

  • TEMPO-2为3期随机双盲安慰剂对照试验,在13个国家75个中心开展,304例早期帕金森病患者按1:1随机接受tavapadon 5-15 mg或安慰剂治疗27周。

主要发现

  • tavapadon组不良事件发生率76%(115/151),安慰剂组55%(84/153);最常见不良事件为恶心(30% vs 3%)、头痛(17% vs 5%)、头晕(16% vs 3%)。
  • tavapadon组因不良事件停药24%(36/151),安慰剂组4%(6/153);滴定期不良事件发生率61%(92/151),高于剂量调整期37%(44/151)和维持期43%(47/151)。

临床怎么用

  • tavapadon可作为早期帕金森病患者的起始治疗选择之一,需注意滴定期的不良事件监测。

局限性

  • 观察期仅27周,无法得出长期耐受性结论;延长研究正在进行中以确认长期安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current dopaminergic therapies for Parkinson's disease carry significant limitations: levodopa can cause long-term motor complications, while D2/D3 receptor-targeting dopamine agonists can produce non-motor adverse effects. Tavapadon is an oral, once-daily, selective D1/D5 agonist that might improve Parkinson's disease motor symptoms. We aimed to evaluate the safety, tolerability and efficacy of flexible-dose tavapadon in people with early-stage Parkinson's disease. METHODS: TEMPO-2 was a phase 3, randomised, double-blind, placebo-controlled trial conducted at 75 clinical sites (both hospital or academic and community settings) across 13 countries. Adults aged 40-80 years with early-stage Parkinson's disease (<3 years' disease duration) who were treatment-naive or had less than 3 months of previous dopaminergic treatment were eligible. Participants were randomly assigned 1:1 to flexible-dose tavapadon (5-15 mg) or placebo orally once daily for 27 weeks. The primary endpoint was change from baseline to week 26 in the combined score of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III (reflecting activities of daily living and motor performance). Safety endpoints included adverse events, clinical laboratory values, vital signs, and electrocardiograms. The primary endpoint was assessed in the modified intent-to-treat population (participants who received one dose or more of study drug and had both a baseline and one or more post-baseline MDS-UPDRS assessments) and safety was assessed in the safety analysis set (all participants who received one dose or more of tavapadon or placebo). This study is registered with ClinicalTrials.gov (NCT04223193) and is now complete. FINDINGS: Between Jan 6, 2020, and Feb 22, 2024, 473 individuals were screened and 304 were randomly assigned to receive tavapadon 5-15 mg (n=151) or placebo (n=153). The majority of participants were male (169 [56%] of 304 male; 135 [44%] of 304 female), the mean age was 62·9 (SD 9·2) years, and the mean disease duration was 0·86 (0·79) years. 80 (26%) of 304 participants discontinued from the trial (57 [38%] of 151 on tavapadon and 23 [15%] of 153 on placebo), most commonly due to adverse events (42 [14%] of 304; 36 [24%] of 151 on tavapadon and six [4%] of 153 on placebo). The primary endpoint of change from baseline to week 26 in the MDS-UPDRS Parts II and III combined score was significantly improved with tavapadon versus placebo (least squares mean [LSM] decrease of 10·3 [95% CI -12·2 to -8·3] points vs 1·2 [-2·9 to 0·6] points; LSM treatment difference -9·1 [95% CI -11·7 to -6·5]; p<0·0001). Most adverse events were non-serious and mild to moderate in severity. More adverse events were observed with tavapadon than with placebo (115 [76%] of 151 participants vs 84 [55%] of 153 participants). The incidence of adverse events in the tavapadon group was higher during the titration phase (92 [61%] of 151) than during the dose adjustment (44 [37%] of 151) and maintenance (47 [43%] of 151) phases. The most commonly reported adverse events with tavapadon versus placebo (>10% of participants) were nausea (45 [30%] of 151] vs five [3%] of 153), headache (25 [17%] vs eight [5%]), and dizziness (24 [16%] vs five [3%]). INTERPRETATION: Tavapadon showed significant and clinically meaningful improvements in Parkinson's disease motor symptoms, with low incidence of somnolence and impulse control disorders. However, the short observation period limits conclusions about long-term tolerability. An ongoing extension study aims to confirm its long-term safety and efficacy. FUNDING: AbbVie.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Fernandez HH, Bhatia P, Cloud L, et al. Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2026. PMID: 42456682. doi:10.1016/S1474-4422(26)00215-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。